You are here

Article Text

Article menu
Supplement
Analysis of duration of risk behaviour for key populations: a literature review
  1. Erika Fazito1,
  2. Paloma Cuchi2,
  3. Mary Mahy2,
  4. Tim Brown3
  1. 1University of Brasília, Brasília, Brazil
  2. 2Department of Epidemic Analysis and Monitoring, UNAIDS, Geneva, Switzerland
  3. 3Research Program, East-West Center, Honolulu, Hawaii, USA
  1. Correspondence to Erika Fazito, University of Brasília, 26 Chemin Colladon, 1209 Genève, Suisse, Brasília, Brazil; erikafazito{at}gmail.com

Abstract

Background The objective of this paper is to review literature in order to calculate regional estimates of the average duration of time individuals maintain a specific high-risk behaviour.

Methods The review targeted the key populations of female sex workers (FSW), male clients of female sex workers (MCFSW), people who inject drugs (injecting drug users (IDU)) and high-risk men who have sex with men (MSM). To be included in the review the study had to provide information on (1) the time a person spent at risk until death or cessation of the risk behaviour, (2) the percentage of the sample who initiated the risk behaviour in less than a year or (3) the mean or median duration of the behaviour from a representative sample.

Results 49 papers were found for the FSW population describing the period of time FSW stay in sex work to be between 2.9 years (Asia) and 12 years (Latin America). Eight papers were found for MCFSW showing the duration of the risk behaviour in this category varying from 4.6 years in Africa to 32 years in Asia. 86 papers were reviewed for the population of IDU showing that the average time a person injects illegal drugs varies from 5.6 years (Africa) to 21 years (South America). No information was found for duration of high-risk behaviour among MSM; instead, the definitions found in the literature for high- and low-risk behaviour among MSM were described.

Conclusions There is high variability of estimates of duration of high-risk behaviours at regional level. More research is needed to inform models and prevention programmes on the average duration of time individuals maintain a specific high-risk behaviour.

  • Injecting Drug Use
  • Prostitution
  • HIV
  • Gay Men

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/3.0/ and http://creativecommons.org/licenses/by-nc/3.0/legalcode

https://doi.org/10.1136/sextrans-2012-050647

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Introduction

    Public health policies must be based on estimates that can support informed decision making and guide HIV prevention resource allocation. The extremely dynamic nature of the HIV epidemic and the various forms it takes in different countries challenge public health managers to find ways to accurately monitor and evaluate its trends. Mathematical modelling plays a central role in this process. It contributes to the understanding of the dynamics of HIV spread, provides the information needed to guide responses, helps to identify gaps in existing knowledge and suggests directions for future research.1

    The Joint United Nations Programme on HIV/AIDS (UNAIDS) develops models (Spectrum2 and Estimation and Projection Package (EPP)3) to analyse HIV epidemics and their impacts for incountry application. These models allow countries to estimate HIV incidence, HIV prevalence, numbers of people living with HIV, numbers of AIDS related deaths, numbers of people in need of antiretroviral therapy (ART), numbers of HIV-positive pregnant women in need of ART prophylaxis and numbers of children orphaned by HIV, along with other programmatically relevant outputs.

    In concentrated epidemics, HIV tends to be focused in a small number of groups with elevated behavioural risk of HIV and their immediate sexual partners. Thus, models of such epidemics must be largely based on information about those key populations: injecting drug users (IDU), high-risk men who have sex with men (MSM), female sex workers (FSW) and their clients (male clients of female sex workers (MCFSW)). However, these populations are often not static. Each year some individuals initiate the behaviours that place them in a behavioural risk group, while others terminate these behaviours, leaving the group; that is, the groups have turnover. Such turnover has significant impacts on the prevalence and incidence in the at-risk population and also in the typically lower-risk populations to which they return.

    Because those entering an elevated risk population are typically coming from a lower-risk, lower prevalence group, they tend to dilute the current prevalence in the at-risk population. Similarly, those leaving the group are often a higher prevalence than the group as a whole because many of them have longer histories of exposure to risk. Both of these effects mean that in order to maintain a fixed prevalence level in an at-risk population, the incidence in the at-risk population must be higher than it would be otherwise. If models are to correctly estimate the incidence in the group for a given pattern of prevalence, then they need to account for these effects. When turnover effects are included, the prevalence curve over time is generally found to flatten out relative to what it would be with no turnover (see figure 1). This is because most HIV mortality that would normally bring down the prevalence in a closed population occurs outside of the at-risk population if the turnover is high, leading to a flatter curve.

    Figure 1
    Figure 1

    HIV prevalence (%) in the injecting drug users (IDU) population by year and turnover input, Thailand.

    In addition, if the prevalence in the group is high, substantial numbers of those leaving the group and returning to a lower-risk population are HIV-positive. This drives prevalence up in the receiving population without incurring additional incidence. In some cases, 10%–20% of the overall prevalence in the receiving population may result from risk behaviours which occurred outside of that population.

    It is essential in concentrated epidemics that models take this into account. Recognising the importance of turnover, the UNAIDS EPP allows users to specify turnover in specific populations. This is done by specifying three things: (1) that turnover does occur in this population; (2) the average time, that is, duration that individuals remain in the at-risk population; and (3) the lower-risk population to which they will return.

    This creates additional data needs for concentrated epidemics where turnover is high and is affecting epidemic dynamics. In addition to data on the size of key populations, data are also required on the average time that people remain in the group. That is, one needs to know how many years a person injects drugs, how many years women stay employed in sex work, how many years MSM engage in unprotected, high-risk anal sex and how many years an MCFSW remains a client. The expectation is that, on average, at the end of that time period a person returns to a lower-risk population group, stopping the behaviours that put the person at a higher risk of contracting HIV.

    In 2009 and 2010, the estimated average duration was based on experts’ opinion because currently countries have very little data on such movements of people in and out of the populations. But given the great impact that this can have on incidence and prevalence, it is critical that the durations used in such models be based on scientific evidence. The objective of this paper is to conduct a review of the literature to generate regional estimates of the average duration that individuals maintain a specific high-risk behaviour before returning to a lower-risk population.

    Methods

    The study is a literature review that aimed to compile the limited available data on duration of high-risk behaviour among key populations.

    The review was performed using PubMed in October 2010. To identify additional pertinent publications, the references listed in the papers found in the search were hand-searched and researchers were contacted to obtain non-published information. Grey literature was also reviewed.

    The studies had to meet the following criteria to be included in the review: (1) to be an original work instead of a literature review; (2) to be studies of one of the key populations important in concentrated epidemics (high-risk MSM, IDU, FSW and MCFSW); and (3) to include information on the duration of risk behaviour or information that could be converted into estimates of duration. Papers in English, Spanish, French and Portuguese were searched with no limits on date. The following search criteria were used:

    • FSW: ((((((((sex workers[Title]) OR sex worker[Title]) OR commercial sex worker[Title]) OR commercial sex workers[Title]) OR sex-trafficked women[Title]) OR prostitutes[Title]) OR prostitution[Title]) OR duration sex work[Title]) OR sex work[Title]

    • IDU: idu[All Fields] OR (inject[All Fields] AND “drugs”[All Fields]) AND users[All Fields] OR (inject[All Fields] AND “drugs”[All Fields] AND user[All Fields])

    • MSM: high [title] AND risk [title] AND “men who have sex with men” [title]

    • CFSW: (“clients”[Title/Abstract] AND prostitutes[Title/Abstract]) OR (“clients”[Title/Abstract] AND (“female”[Title/Abstract] AND “sex”[Title/Abstract] AND workers”[Title/Abstract]

    Information on the study design, year of data collection, location, turnover, sample definition, age and gender was collected and summarised in tables that can be accessed online as supplementary tables for this paper (see online supplementary tables S1, S2 and S3).

    The ideal studies to assess duration of high-risk behaviour would be surveys of former members of these key populations. The question asked would be how long they had engaged in the high-risk behaviour. In the literature review, for all groups except for IDU, no papers on former members of these key populations were found. Hence, instead of searching for data from which to actually estimate average duration of behaviour, it was necessary to search for data from surveys of current key populations that included information indicating how long the respondent had been at risk. This information was given in three different ways, depending on the study. Some authors calculated the mean or median time the respondents had been at risk, some demonstrated the percentage of the sample who started the risk behaviour in the last year and a few described the duration of the behaviour as the amount of time a person spent in the risk behaviour group until death or cessation.

    Because of the diverse presentation of results, it was necessary to create an algorithm to decide how to use the results and choose the best estimate for each region. The first method of choice was direct estimation of duration (the time a person spent at risk until death or cessation of risk behaviour). This required that the person had already discontinued the behaviour that put them in that group.

    If the first method was not available, the second method of choice would be used. This consisted of estimating the duration of risk behaviour by the percentage of the sample who initiated the risk behaviour in less than a year. If the population is not changing size, that is, is in a steady state, this percentage will equal the percentage who stopped the behaviour in the last year. In a steady state the entries must equal exits and thus the duration will be 1/(the proportion), so if 10% entered, then the average duration will be 1/0.1=10 years.

    If data to apply the first two methods were not available, a third method was used to estimate turnover. The third method consisted of doubling the median or mean time the people remained in the risk behaviour group in the moment of the study interview. This assumes that the duration of time in the key population is randomly distributed and has a normal distribution. It is recognised that this assumption may often be violated as the distribution of time in a group is often heavily skewed toward lower durations, with many people entering the groups for a short period and then ceasing the corresponding risk behaviours. Because of that assumption we used primarily the median and in its absence the mean to calculate duration. The results for the third method are presented in a range formed by the mean and the median of the duration of the datasets.

    If data were available, all three methods were applied for all the regions and key populations. The duration of high-risk behaviour has been derived for the following geographic regions: America, Europe, Asia, Australia/Oceania and Africa. When possible, the basic regions were unfolded to depict more specific information.

    Results

    Female sex workers

    In all, 31 papers were found for Africa and they generated information about 47 different datasets.

    • Four papers described the percentage of FSW who started selling sex in the last year.4–7 Based on these studies the mean duration for FSW is estimated to be 5.5 years.

    • Using the third method proposed, 43 datasets provided the average duration of sex work.8–29 This period ranged from 0.3 to 6.0 years, with a mean and a median of 2.9 years which resulted in an average duration of 5.5 years.

    A total of 40 papers were found on Asia which generated information from 48 different datasets.

    • Twelve papers described the percentage of FSW who started selling sex in the last year. Based on that information, the mean duration for FSW was 2.94 years and ranged from 1.35 to 12.05 years according to the dataset.30–40

    • Thirty-one datasets showed the average duration spent in sex work. This period ranged from zero to 6.5 years, with a mean of 2 years and a median of 1.4 years which would lead to a duration between 2.8 and 4.0 years.37 ,41–63

    Nine papers were found on Europe and they generated information on 10 different datasets, showing the average duration of sex work. This period ranged from 1.5 to 12 years, with a mean of 5 years and a median of 4.2 years, which would lead to a duration between 8.4 and 10 years.64–72

    Six papers were found for Latin America, describing the average time FSW spend in business. This period varied from 3.5 to 8.8 years according to the dataset, with a mean of 6 years and a median of 5.6 years, which would lead to a duration of risk behaviour between 11.2 and 12 years.73–79

    Three papers were found in North America, showing the duration of sex work up to the interview in median years. The median ranged from 5 to 6.4 years with a mean of 5.5 years and a median of 5.1 years. If we consider this distribution to be normal and double the values to reach turnover, the estimated duration of risk behaviour is between 10.2 and 11 years.80–82

    No papers were found for Oceania/Australia.

    In summary, it was possible to generate estimates for duration of risk behaviour for five regions. The results are presented in table 1.

    View this table:
    Table 1

    Regional estimates of duration of risk behaviour for FSW by the method of calculation

    Male clients of female sex workers

    Eight papers were found describing the median or mean duration during which men routinely bought sex: three in America83–85 (two in Mexico and one in Haiti), three for Asia/Oceania86–88 (China, India and Australia) and two for Africa89 ,90 (Benin and Kenya).

    In America this period ranged from 6.3 to 10.8 years, with a mean of 8 years which leads to an estimated duration of risk behaviour of 16 years. For Asia/Oceania, the estimated duration ranged from 9.0 to 30 years, with a mean of 16.2 years which leads to a duration of 32.4 years.

    One paper from Africa described the percentage of men who started paying for sex in the year prior to the survey (21.9%) suggesting a duration of 4.6 years.

    Estimates on duration of risk behaviour are presented in table 2. However, given the low number of studies and wide variability, these findings must be interpreted with caution. More country-specific data are urgently needed for this population.

    View this table:
    Table 2

    Regional estimates of duration of risk behaviour for MCFSW by the method of calculation

    Injecting drugs users

    In most of the world, more duration information was available for IDU compared with other key populations; however, there was substantial geographic variation in the number of studies conducted. Only two papers were found on IDU in Africa91 ,92 and one provided the percentage of IDU who started injecting drugs in the year prior to the survey: 18%.93 Based on that information, the turnover for IDU was estimated to be 5.6 years.

    Overall, 16 papers were found on IDU in Asia and they generated information on 23 different datasets.

    • Six datasets described the percentage of IDU who started injecting drugs in the year prior to the survey.92 ,94 Based on that information, the mean turnover for IDU was estimated to be 8.7 years with a range from 3.7 to 22.2 years.

    • In all, 17 datasets showed the average time a person spent injecting drugs.95–107 This period ranged from 1.9 to 17.0 years, with a mean of 6.8 years and a median of 4.4 years suggesting turnover between 8.8 and 13.6 years.

    A total of 12 papers were found in Oceania, all conducted in Australia, generating 15 different datasets.

    • A study conducted in Australia108 aimed to examine mortality within the 626 IDU from the Victorian Injecting Drug Users Cohort Study (VICS). They retrospectively examined mortality comparing data from the VICS, recruited from 1990 to 1995, to data from the National Death Index containing records of all deaths in Australia from 1990 to 2006. A total of 26 IDU died before the end of 2006 and the average length of injecting career at death was 17.0 years (SD=7.05, min 3.86, max 29.79); 18 of the 26 deaths were drug-related.

    • One paper109 described the percentage of IDU who started injecting drugs in the last year. Based on that information, the turnover for IDU was estimated to be 5.2.

    • Thirteen datasets showed the average time a person spent injecting drugs.110–119 This period ranged from 2.4 to 15 years, with a mean of 9.1 years and a median of 8 years suggesting a turnover between 16 and 18.2 years.

    A total of 24 papers were found in Europe generating 37 different databases.

    • A study conducted in Scotland aimed to identify the mortality risk and explore the causes of death in all IDU who attended a family medical practice in northwest Edinburgh.120 They were followed for 21 years, and the mean time from first injection until death was 13.9 years.

    • Four datasets described the percentage of IDU who started injecting drugs in the year prior to the survey.121–123 Based on that information, the mean turnover for IDU was estimated to be 8.9 years.

    • Thirty-two datasets124–142 described the mean duration of injecting career up to the moment of the interview. It varied from 1.3 to 14.3 years, leading to a mean and a median of 8.6 years. If we consider this distribution to be normal and double the value to reach turnover, the estimated turnover would be 17.2 years.

    Six papers were found on South America generating nine different datasets and they all described the duration of injecting career up to the moment of the interview by medians and means. This period ranged from 2.2 to 21 years, with a mean of 10.5 years and a median of 9.8 years suggesting turnover between 21 and 19.6 years.143–148

    A total of 26 papers were found in North America generating 34 different datasets.

    • A prospective study conducted in the USA aimed to examine both the incidence of injection cessation and the change in injection frequency among those who did not quit injection.149 The study included 901 IDUs who were recruited from a Needle Exchange Program (NEP) or an area with no NEP in Chicago between 1997 and 2002. Cessation of injection, the main outcome variable, was defined as no injection drug use since the last interview (1 year prior). In all, 116 IDUs ceased injection during the study, and the median number of years from first injection until cessation was 9.5 years.

    • Five datasets described the percentage of IDU who started injecting drugs in the last year.150–153 Based on that information, the mean duration for IDU was 4.7 years.

    • 33 datasets showed the average time a person spent injecting drugs.133 ,152–173 This period ranged from 1.3 to 23.9 years, with a median of 4.4 years and mean of 7 years, suggesting a duration between 8.8 and 14 years.

    Duration estimates were generated for six regions. The results are presented in table 3.

    View this table:
    Table 3

    Regional estimates of duration of risk behaviour for IDU by the method of calculation

    High-risk MSM

    MSM are also a key population because of the increased risk of HIV transmission through anal intercourse. However, anal intercourse can be safe when between faithful, uninfected partners or when consistent condom use is practiced. A literature review was completed of surveys of MSM looking for the turnover between high-risk MSM and low-risk MSM. However, no studies assessing turnover for this population were found. At this point it is not possible to estimate average duration in the high-risk MSM population. We decided then to compile the different definitions used in surveys for high- and low-risk MSM to contribute to the characterisation of these two different patterns of sexual behaviour among the MSM population. The MSM sexual practices are described below according to the risk of exposure to HIV.174–181

    High-risk sexual behaviours

    • Barebacking

    • Unprotected anal intercourse (UAI) with an HIV-seropositive partner

    • Rimming (anal/oral sex play)

    • Fisting (insertion of the hand into the anus)

    • Use of sex toys and shared drug implements

    • UAI with casual partners

    • UAI with partners of an unknown or discordant HIV status

    • Having multiple sex partners

    • Trading sex

    • Having unprotected anal sex and anal sex while drunk or high in the past 6 months

    Low-risk sexual behaviours

    • Men who had been involved in a mutually monogamous relationship for 2 or more years with a male partner known to be negative for HIV antibodies.

    • Men who had been involved in a mutually monogamous relationship for 2 or more years with a male partner under ART treatment.

    Very few studies cover duration of risk behaviours for male sex workers and transvestites and therefore were not included in the study.

    Discussion

    This literature review provides estimates of the average duration people spend in high-risk behaviours categories by mode of exposure and geographical region. As described earlier, mathematical models of the HIV epidemic can use this information to estimate changes in the epidemic due to new susceptibles entering (ie, the population newly joining the high-risk populations) and older, higher prevalence members leaving. Spectrum/EPP, a model used by over 150 countries, requires this as an input for countries with concentrated HIV epidemics if the user wishes to apply turnover in their fits. This paper provides a more scientific basis for making turnover estimates using published and unpublished data that can be used by countries as inputs for the Spectrum/EPP model.

    The results of the review showed that average duration of female sex work varies dramatically by region with the shortest durations (and highest turnover) found in Asia and the longest average duration of sex work found in the Americas.

    Similarly, the average duration of injecting drug use varies by region. In Africa, average duration of injecting drug use was approximately 6 years while in South America and Oceania the duration was closer to 20 years. Large differences in turnover have important implications for prevention activities and services for key populations. In areas with very high turnover more frequent outreach activities and surveillance activities are required. Where turnover is slower, activities can focus more on reaching divergent subgroups of the key populations to ensure the entire population is reached with services.

    The variability of these estimates at regional level suggests that there are substantial differences at national levels as well. Differences in duration might be due to different public health interventions by region, country or subnational level or due to different reasons for the high-risk behaviour such as financial need for sex work or poor future prospects for injecting drug use. Also, duration of injecting drug use is highly dependent on mortality, thus the differences in average injecting drug duration could be associated with differences in healthcare for the injecting drug population.

    This study has several limitations. First, the definitions of key populations present minor variations among the different surveys analysed. Also, it is important to highlight that for the calculation of duration of risk behaviour for FSW, some studies that included FSW who practice injecting drug use were included. Similarly, studies on IDU who practice commercial sex work were included in the calculations of the average duration of time of injecting drugs. It was decided not to separate such information because the estimates of duration of risk behaviour calculated in this study are intended to serve as input for mathematical HIV/AIDS models. In such models, the stratification of an epidemic structure, in terms of populations, can be made as far as strategic information is available for each population. And rarely do countries have detailed information about HIV prevalence and population size for, for example, the sex workers who use injected drugs and the ones who do not.

    Another point to be addressed is the differences found between the estimates generated by methods 2 and 3. These methods generated most of the time similar estimates of duration of risk behaviour, except for the population of IDU in Asia, Oceania and North America. In these regions, the estimates of duration calculated by method 2 are lower than the ones calculated by methods 1 and 3. One possible explanation is that the assumption of stability is being violated. In this case, method 2 may be underestimating duration. Given the limited number of studies allowing method 2 to be used, another likely explanation is that the specific populations of IDU being examined in the different papers have widely varying durations. In those few cases where data were available to apply both methods 2 and 3 the variation was not as extreme as the table averages would imply. And as (1) populations of IDU and FSW are likely to fluctuate due to economic changes, legal changes, changes in demand and changes in supply for the behaviour and (2) many samples are censored, the estimates of duration calculated by methods 2 and 3 among FSW and IDU should be compared which determine whether violations of the assumption of a steady state have a significant impact on the estimates.

    Another limitation is that the estimates for MCFSW must be interpreted cautiously due to two reasons. First, to the low number of studies found. And second, because in many countries, young men may go through a period during which they frequent sex workers often, but then this behaviour ceases or slows once they marry. In countries where this is the most common male behavioural pattern, a better estimator of duration of high-risk behaviour for this population may be the difference between average age at first intercourse and average age at marriage.

    Last, it is important to highlight that very few surveys collect data on duration of high-risk behaviour and thus the analysis was limited to the countries that have been collecting these data. Therefore, the geographical coverage in this review is limited to a few countries that have collected information on duration or time since initiation of risk behaviour.

    Despite the many limitations to the calculations presented in this paper, these are, to the authors’ knowledge, the best available estimates of durations of risk behaviours. One important implication of this review is the need to include questions from which to estimate duration of risk behaviour in surveys among members of key populations in concentrated epidemics. These questions should be, for example: How long have you been exchanging sex for money? How long have you been injecting illegal drugs? How long have you been buying sex from FSW? From these questions, it is possible to demonstrate the proportion of members who have had the behaviour for less than 12 months and easily calculate duration of risk behaviour.

    More research on turnover among key populations is needed to inform both models and prevention programmes. Future reviews on this subject should attempt to identify surveys in other databases such as Embase and Medline, rather than PubMed, and should also search for additional grey literature.

    Key messages

    • This paper provides a more scientific basis for making turnover estimates using data that can be used by countries as inputs for the Spectrum/Estimation and Projection Package model.

    • There is high variability of estimates of duration of high-risk behaviours at regional level.

    • More research is needed to inform models and prevention programmes on the average duration of time individuals maintain a specific high-risk behaviour.

    References

    1. ↵
      1. Clark SJ,
      2. Morris M
      . Mathematical models for HIV transmission dynamics: tools for social and behavioral science research. J Acquir Immune Defic Syndr 2008;47(Suppl 1):S34–9.
      OpenUrlCrossRefPubMedWeb of Science
    2. ↵
      1. Stover J,
      2. Johnson P,
      3. Hallett T,
      4. et al
      . The Spectrum projection package: improvements in estimating incidence by age and sex, mother-to-child transmission, HIV progression in children and double orphans. Sex Transm Infect 2010;86(Suppl 2):ii16–21.
      OpenUrlAbstract/FREE Full Text
    3. ↵
      1. Brown T,
      2. Bao L,
      3. Raftery AE,
      4. et al
      . Modeling HIV epidemics in the antiretroviral era: the UNAIDS estimation and projection package 2009. Sex Transm Infect 2010;86(Suppl 2):ii3–10.
      OpenUrlAbstract/FREE Full Text
    4. ↵
      1. Delaporte E,
      2. Buvé A,
      3. Nzila N,
      4. et al
      . HTLV-I infection among prostitutes and pregnant women in Kinshasa, Zaïre: how important is high-risk sexual behavior? J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:511–15. PubMed PMID: 7697449.
      OpenUrlPubMedWeb of Science
    5. ↵
      1. Nagot N,
      2. Ouangré A,
      3. Ouedraogo A,
      4. et al
      . Spectrum of commercial sex activity in burkina faso: classification model and risk of exposure to HIV. J Acquir Immune Defic Syndr 2002;29:517–21.
      OpenUrlCrossRefPubMedWeb of Science
    6. ↵
      1. Kayembe PK,
      2. Mapatano MA,
      3. Busangu AF,
      4. et al
      . Determinants of consistent condom use among female commercial sex workers in the Democratic Republic of Congo: implications for interventions. Sex Transm Infect 2008;84:202–6. Epub 2007 Nov 30.
      OpenUrlAbstract/FREE Full Text
    7. ↵
      1. Pepin J,
      2. Dunn D,
      3. Gaye I,
      4. et al
      . HIV-2 infection among prostitutes working in The Gambia: association with serological evidence of genital ulcer diseases and with generalized lymphadenopathy. AIDS 1991;5:69–75.
      OpenUrlCrossRefPubMedWeb of Science
    8. ↵
      1. Dada AJ,
      2. Ajayi AO,
      3. Diamondstone L,
      4. et al
      . A Serosurvey of Haemophilus ducreyi, Syphilis, and Herpes Simplex Virus Type 2 and their association with human immunodeficiency virus among female sex workers in Lagos, Nigeria. Sex Transm Dis 1998;25:237–42.
      OpenUrlPubMedWeb of Science
    9. ↵
      1. Fowke KR,
      2. Nagelkerke NJ,
      3. Kimani J,
      4. et al
      . Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet 1996;348:1347–51. PubMed PMID: 8918278.
      OpenUrlCrossRefPubMedWeb of Science
    10. ↵
      1. Jennes W,
      2. Sawadogo S,
      3. Koblavi-Dème S,
      4. et al
      . Cellular human immunodeficiency virus (HIV)-protective factors: a comparison of HIV-exposed seronegative female sex workers and female blood donors in Abidjan, Côte d'Ivoire. J Infect Dis 2003;187:206–14. Epub 2002 Dec 30. PubMed PMID: 12552445.
      OpenUrlAbstract/FREE Full Text
    11. ↵
      1. Lavreys L,
      2. Chohan V,
      3. Overbaugh J,
      4. et al
      . Hormonal contraception and risk of cervical infections among HIV-1-seropositive Kenyan women. AIDS 2004;18:2179–84. PubMed PMID: 15577651373.
      OpenUrlCrossRefPubMedWeb of Science
    12. ↵
      1. Kaul R,
      2. Kimani J,
      3. Nagelkerke NJ,
      4. et al
      . Risk factors for genital ulcerations in Kenyan sex workers. The role of human immunodeficiency virus type 1 infection. Sex Transm Dis 1997;24:387–92. PubMed PMID: 9263358.
      OpenUrlCrossRefPubMedWeb of Science
    13. ↵
      1. Jennes W,
      2. Vuylsteke B,
      3. Borget MY,
      4. et al
      . HIV-specific T helper responses and frequency of exposure among HIV-exposed seronegative female sex workers in Abidjan, Cote d'Ivoire. J Infect Dis 2004;189:602–10. Epub 2004 Jan 29. PubMed PMID:14767812.
      OpenUrlAbstract/FREE Full Text
    14. ↵
      1. Ghys PD,
      2. Diallo MO,
      3. Ettiègne-Traoré V,
      4. et al
      . Increase in condom use and decline in HIV and sexually transmitted diseases among female sex workers in Abidjan, Côte d'Ivoire, 1991–1998. AIDS 2002;16:251–8. PubMed PMID: 11807310.
      OpenUrlCrossRefPubMedWeb of Science
    15. ↵
      1. Asamoah-Adu C,
      2. Khonde N,
      3. Avorkliah M,
      4. et al
      . HIV infection among sex workers in Accra: need to target new recruits entering the trade. J Acquir Immune Defic Syndr 2001;28:358–66. PubMed PMID: 11707673.
      OpenUrlPubMed
    16. ↵
      1. Mulanga-Kabeya C,
      2. Morel E,
      3. Patrel D,
      4. et al
      . Prevalence and risk assessment for sexually transmitted infections in pregnant women and female sex workers in Mali: is syndromic approach suitable for screening? Sex Transm Inf 1999;75:358–60.
      OpenUrlPubMedWeb of Science
    17. ↵
      1. Cameron DW,
      2. Ngugi EN,
      3. Ronald AR,
      4. et al
      . Condom use prevents genital ulcers in women working as prostitutes: influence of human immunodeficiency virus infection. Sex Transm Dis 1991;18:188–91.
      OpenUrlCrossRefPubMed
    18. ↵
      1. Ramjee G,
      2. Williams B,
      3. Gouws E,
      4. et al
      . The impact of incident and prevalent herpes simplex virus-2 infection on the incidence of HIV-1 infection among commercial sex workers in South Africa. J Acquir Immune Defic Syndr 2005;39:333–9. PubMed PMID: 15980695.
      OpenUrlCrossRefPubMedWeb of Science
    19. ↵
      1. Phillipon M,
      2. Saada M,
      3. Ali Kamil M,
      4. et al
      . Fréquentation de un centre de santé par lês prostituées clandestines à Djibouti. Cahiers Santé 1997;7; 5:10.
      OpenUrl
    20. ↵
      1. Nzila N,
      2. Laga M,
      3. Thiam MA,
      4. et al
      . HIV and other sexually transmitted diseases among female prostitutes in Kinshasa. AIDS 1991;5:715–21.
      OpenUrlPubMedWeb of Science
    21. ↵
      1. Kanki P,
      2. M'Boup S,
      3. Marlink R,
      4. et al
      . Prevalence and risk determinants of human immunodeficiency virus type 2 (HIV-2) and human immunodeficiency virus type 1 (HIV-1) in west African female prostitutes. Am J Epidemiol 1992;136:895–907. PubMed PMID: 1442755.
      OpenUrlAbstract/FREE Full Text
    22. ↵
      1. Willerford D,
      2. Bwayo JJ,
      3. Hensel M,
      4. et al
      . Human immunodeficiency virus infection among high-risk seronegative prostitutes in Nairobi. JID 1993;167:1414–7.
      OpenUrlAbstract/FREE Full Text
    23. ↵
      1. Simonsen JN,
      2. Plummer FA,
      3. Ngugi EN,
      4. et al
      . HIV infection among lower socioeconomic strata prostitutes in Nairobi. AIDS 1990;4:139–44. PubMed PMID: 2328096.
      OpenUrlCrossRefPubMedWeb of Science
    24. ↵
      1. Baeten JM,
      2. Richardson BA,
      3. Martin HL,
      4. et al
      . Trends in HIV-1 incidence in a cohort of prostitutes in Kenya: implications for HIV-1 vaccine efficacy trials. J Acquir Immune Defic Syndr 2000;24:458–64.
      OpenUrlPubMedWeb of Science
    25. ↵
      1. Anzala OA,
      2. Nagelkerke NJ,
      3. Bwayo JJ,
      4. et al
      . Rapid progression to disease in African sex workers with human immunodeficiency virus type 1 infection. J Infect Dis 1995;171:686–9. Erratum in: J Infect Dis 1996;173:1529. PubMed PMID:7876618.
      OpenUrlAbstract/FREE Full Text
    26. ↵
      1. Ngugi EN,
      2. Plummer FA,
      3. Simonsen JN,
      4. et al
      . Prevention of transmission of human immunodeficiency virus in Africa: effectiveness of condom promotion and health education among prostitutes. Lancet 1988;2:887–90.
      OpenUrlPubMedWeb of Science
    27. ↵
      1. Mann JM,
      2. Nzilambi N,
      3. Piot P,
      4. et al
      . HIV infection and associated risk factors in female prostitutes in Kinshasa, Zaire. AIDS 1988;2:249–54.
      OpenUrlPubMedWeb of Science
    28. ↵
      1. Langley CL,
      2. Benga-De E,
      3. Critchlow CW,
      4. et al
      . HIV-1, HIV-2, human papillomavirus infection and cervical neoplasia in high-risk African women. AIDS 1996;10:413–17.
      OpenUrlCrossRefPubMedWeb of Science
    29. ↵
      1. Alary M,
      2. Mukenge-Tshibaka L,
      3. Bernier F,
      4. et al
      . Decline in the prevalence of HIV and sexually transmitted diseases among female sex workers in Cotonou, Benin, 1993–1999. AIDS 2002;16:463–70.
      OpenUrlCrossRefPubMedWeb of Science
    30. ↵
      1. Ohshige K,
      2. Morio S,
      3. Mizushima S,
      4. et al
      . Cross-sectional study on risk factors of HIV among female commercial sex workers in Cambodia. Epidemiol Infect 2000;124:143–52. PubMed PMID: 10722142; PubMed Central PMCID: PMC2810895.
      OpenUrlPubMed
    31. ↵
      1. Ohshige K,
      2. Morio S,
      3. Mizushima S,
      4. et al
      . Behavioural and serological human immunodeficiency virus risk factors among female commercial sex workers in Cambodia. Int J Epidemiol 2000;29:344–54. PubMed PMID: 10817135.
      OpenUrlAbstract/FREE Full Text
    32. ↵
      1. Sarkar K,
      2. Bal B,
      3. Mukherjee R,
      4. et al
      . Young age is a risk factor for HIV among female sex workers–an experience from India. J Infect 2006;53:255–9. Epub 2005 Dec 27. PubMed PMID: 16386307.
      OpenUrlCrossRefPubMedWeb of Science
    33. ↵
      1. Lau JT,
      2. Zhang J,
      3. Zhang L,
      4. et al
      . Comparing prevalence of condom use among 15,379 female sex workers injecting or not injecting drugs in China. Sex Transm Dis 2007;34:908–16. PubMed PMID: 18049424.
      OpenUrlCrossRefPubMedWeb of Science
    34. ↵
      1. Sarkar K,
      2. Bhattacharya S,
      3. Bhattacharyya S,
      4. et al
      . Oncogenic human papilloma virus and cervical pre-cancerous lesions in brothel-based sex workers in India. J Infect Public Health 2008;1:121–8. Epub 2008 Nov 12. PubMed PMID: 20701853.
      OpenUrlCrossRefPubMed
    35. ↵
      1. Silverman JG,
      2. Decker MR,
      3. Gupta J,
      4. et al
      . HIV prevalence and predictors among rescued sex-trafficked women and girls in Mumbai, India. J Acquir Immune Defic Syndr 2006;43:588–93. PubMed PMID: 17019369.
      OpenUrlPubMedWeb of Science
    36. ↵
      1. Celentano DD,
      2. Akarasewi P,
      3. Sussman L,
      4. et al
      . HIV-1 infection among lower class commercial sex workers in Chiang Mai, Thailand. AIDS 1994;8:533–7. PubMed PMID: 8011259.
      OpenUrlPubMedWeb of Science
    37. ↵
      1. Nakashima K,
      2. Kashiwagi S,
      3. Hayashi J,
      4. et al
      . Sexual transmission of hepatitis C virus among female prostitutes and patients with sexually transmitted diseases in Fukuoka, Kyushu, Japan. Am J Epidemiol 1992;136:1132–7.
      OpenUrlAbstract/FREE Full Text
    38. ↵
      1. Wang H,
      2. Chen RY,
      3. Ding G,
      4. et al
      . Prevalence and predictors of HIV infection among female sex workers in Kaiyuan City, Yunnan Province, China. Int J Infect Dis 2009;13:162–9. Epub 2008 Aug 20. PubMed PMID: 18718801; PubMed Central PMCID: PMC2650737.
      OpenUrlCrossRefPubMedWeb of Science
    39. ↵
      1. Taneepanichskul S,
      2. Phuapradit W,
      3. Chaturachinda K
      . Association of contraceptives and HIV-1 infection in Thai female commercial sex workers. Aust N Z J Obstet Gynaecol 1997;37:86–8. PubMed PMID: 9075554.
      OpenUrlCrossRefPubMed
    40. ↵
      1. Simoes EA,
      2. Babu PG,
      3. Jeyakumari HM,
      4. et al
      . The initial detection of human immunodeficiency virus 1 and its subsequent spread in prostitutes in Tamil Nadu, India. J Acquir Immune Defic Syndr 1993;6:1030–4.
      OpenUrlPubMed
    41. ↵
      Cambodia Ministry of Health 1998.
    42. ↵
      Cambodia Ministry of Health 1997.
    43. ↵
      Cambodia Ministry of Health 1999.
    44. ↵
      Cambodia Ministry of Health 2001.
    45. ↵
      Cambodia Ministry of Health 2003.
    46. ↵
      Cambodia Ministry of Health 2007.
    47. ↵
      1. Kao JH,
      2. Chen W,
      3. Chen PJ,
      4. et al
      . GB virus-C/hepatitis G virus infection in prostitutes: possible role of sexual transmission. J Med Virol 1997;52:381–4. PubMed PMID: 9260684.
      OpenUrlCrossRefPubMedWeb of Science
    48. ↵
      1. Majid N,
      2. Bollen L,
      3. Morineau G,
      4. et al
      . Syphilis among female sex workers in Indonesia: need and opportunity for intervention. Sex Transm Infect 2010;86:377–83.
      OpenUrlAbstract/FREE Full Text
    49. ↵
      1. Mishra S,
      2. Moses S,
      3. Hanumaiah PK,
      4. et al
      . Sex work, Syphilis, and seeking treatment: an opportunity for intervention in HIV prevention programming in Karnataka, South India. Sex Transm Dis 2009;36:157–64.
      OpenUrlCrossRefPubMed
    50. ↵
      1. Nhurod P,
      2. Bollen LJ,
      3. Smutraprapoot P,
      4. et al
      . Access to HIV testing for sex workers in Bangkok, Thailand: a high prevalence of HIV among street-based sex workers. Southeast Asian J Trop Med Public Health 2010;41:153–62. PubMed PMID: 20578494.
      OpenUrlPubMedWeb of Science
    51. ↵
      1. Reza-Paul S,
      2. Beattie T,
      3. Syed HU,
      4. et al
      . Declines in risk behaviour and sexually transmitted infection prevalence following a community-led HIV preventive intervention among female sex workers in Mysore, India. AIDS 2008;22(Suppl 5):S91–100.
      OpenUrlCrossRefPubMedWeb of Science
    52. ↵
      1. Ruan Y,
      2. Cao X,
      3. Qian HZ,
      4. et al
      . Syphilis among female sex workers in southwestern China: potential for HIV transmission. Sex Transm Dis 2006;33:719–23. PubMed PMID: 16708055.
      OpenUrlCrossRefPubMedWeb of Science
    53. ↵
      1. Rugpao S,
      2. Pruithithada N,
      3. Yutabootr Y,
      4. et al
      . Condom breakage during commercial sex in Chiang Mai, Thailand. Contraception 1993;48:537–47. PubMed PMID: 8131395.
      OpenUrlCrossRefPubMedWeb of Science
    54. ↵
      1. Sawayama Y,
      2. Hayashi J,
      3. Etoh Y,
      4. et al
      . Heterosexual transmission of GB virus C/hepatitis G virus infection to non-intravenous drug-using female prostitutes in Fukuoka, Japan. Dig Dis Sci 1999;44:1937–43.
      OpenUrlCrossRefPubMed
    55. ↵
      1. Silverman JG,
      2. Decker MR,
      3. Gupta J,
      4. et al
      . HIV prevalence and predictors of infection in sex-trafficked Nepalese girls and women. JAMA 2007;298:536–42. PubMed PMID: 17666674.
      OpenUrlCrossRefPubMedWeb of Science
    56. ↵
      1. Sopheab H,
      2. Gorbach PM,
      3. Gloyd S,
      4. et al
      . Rural sex work in Cambodia: work characteristics, risk behaviours, HIV, and syphilis. Sex Transm Infect 2003;79:e2. PubMed PMID: 12902610; PubMed Central PMCID: PMC1744694.
      OpenUrlAbstract/FREE Full Text
    57. ↵
      1. Thuy NT,
      2. Nhung VT,
      3. Thuc NV,
      4. et al
      . HIV infection and risk factors among female sex workers in southern Vietnam. AIDS 1998;12:425–32.
      OpenUrlPubMedWeb of Science
    58. ↵
      1. Todd CS,
      2. Nasir A,
      3. Stanekzai MR,
      4. et al
      . HIV, hepatitis B, and hepatitis C prevalence and associated risk behaviors among female sex workers in three Afghan cities. AIDS 2010;24(Suppl 2):S69–75. PubMed PMID: 20610952.
      OpenUrlCrossRefPubMedWeb of Science
    59. ↵
      1. Tran TN,
      2. Detels R,
      3. Long HT,
      4. et al
      . HIV infection and risk characteristics among female sex workers in Hanoi, Vietnam. J Acquir Immune Defic Syndr 2005;39:581–6. PubMed PMID: 16044011; PubMed Central PMCID: PMC2908502.
      OpenUrlPubMedWeb of Science
    60. ↵
      1. van den Hoek A,
      2. Yuliang F,
      3. Dukers NH,
      4. et al
      . High prevalence of syphilis and other sexually transmitted diseases among sex workers in China: potential for fast spread of HIV. AIDS 2001;15:753–9. PubMed PMID: 11371690.
      OpenUrlCrossRefPubMedWeb of Science
    61. ↵
      1. Wang BO,
      2. Xiaoming LI,
      3. Stanton B,
      4. et al
      . Vaginal douching, condom use, and sexually transmitted infections among chinese female sex workers. Sex Transm Dis 2005;32:696–702.
      OpenUrlCrossRefPubMedWeb of Science
    62. ↵
      1. Wong ML,
      2. Chan RK,
      3. Koh D,
      4. et al
      . A prospective study on condom slippage and breakage among female brothel-based sex workers in Singapore. Sex Transm Dis 2000;27:208–14. PubMed PMID: 10782742.
      OpenUrlCrossRefPubMed
    63. ↵
      1. Tran TT,
      2. Le CL,
      3. Nguyen TL
      . Factors associated with inconsistent condom use among female sex workers in Nha Trang, Vietnam. Asia Pac J Public Health 2008;20:370–8.
      OpenUrlAbstract/FREE Full Text
    64. ↵
      1. Baars JE,
      2. Boon BJ,
      3. Garretsen HF,
      4. et al
      . Vaccination uptake and awareness of a free hepatitis B vaccination program among female commercial sex workers. Womens Health Issues 2009;19:61–9. Epub 2008 Oct 25. PubMed PMID: 18951815.
      OpenUrlCrossRefPubMedWeb of Science
    65. ↵
      1. Vioque J,
      2. Hernández-Aguado I,
      3. Fernandez García E,
      4. et al
      . Prospective cohort study of female sex workers and the risk of HIV infection in Alicante, Spain (1986–96). Sex Transm Infect 1998;74:284–8.
      OpenUrlAbstract
    66. ↵
      1. Ward H,
      2. Day S,
      3. Mezzone J,
      4. et al
      . Prostitution and risk of HIV: female prostitutes in London. BMJ 1993;307:356–8. PubMed PMID: 8374417; PubMed Central PMCID: PMC1678221.
      OpenUrlAbstract/FREE Full Text
    67. ↵
      1. Ward H,
      2. Day S
      . What happens to women who sell sex? Report of a unique occupational cohort. Sex Transm Infect 2006;82:413–17. Epub 2006 Jun 21. PubMed PMID: 16790559; PubMed Central PMCID: PMC2563855.
      OpenUrlAbstract/FREE Full Text
    68. ↵
      1. Pineda JA,
      2. Rivero A,
      3. Rey C,
      4. et al
      . Association between hepatitis C virus seroreactivity and HIV infection in non-intravenous drug abusing prostitutes. Eu J Clin Microbiol Infect Dis 1995;14:460–4, doi: 10.1007/BF02114907
      OpenUrlCrossRef
    69. ↵
      1. Uusküla A,
      2. Fischer K,
      3. Raudne R,
      4. et al
      . A study on HIV and hepatitis C virus among commercial sex workers in Tallinn. Sex Transm Infect 2008;84:189–91. Epub 2008 Feb 6. PubMed PMID: 18256109.
      OpenUrlAbstract/FREE Full Text
    70. ↵
      1. McKeganey N,
      2. Barnard M
      . Selling sex: female street prostitution and HIV risk behaviour in Glasgow. AIDS Care 1992;4:395–407. PubMed PMID: 1493147.
      OpenUrlPubMedWeb of Science
    71. ↵
      1. Papaevangelou G,
      2. Roumeliotou A,
      3. Kallinikos G,
      4. et al
      . Education in preventing HIV infection in greek registered prostitutes. J Acquir Immune Defic Syndr 1988;1:386–9.
      OpenUrlPubMed
    72. ↵
      1. Pineda JA,
      2. Aguado I,
      3. Rivero A,
      4. et al
      . HIV-1 infection among non-intravenous drug user female prostitutes in Spain. No evidence of evolution to Pattern II. AIDS 1992;6:1365–9.
      OpenUrlCrossRefPubMedWeb of Science
    73. ↵
      1. Loza O,
      2. Patterson TL,
      3. Rusch M,
      4. et al
      . Proyecto Mujer Segura. Drug-related behaviors independently associated with syphilis infection among female sex workers in two Mexico-US border cities. Addiction 2010;105:1448–56. Epub 2010 Apr 27. PubMed PMID: 20456292.
      OpenUrlCrossRefPubMedWeb of Science
    74. ↵
      1. Bucardo J,
      2. Semple SJ,
      3. Fraga-Vallejo M,
      4. et al
      . A qualitative exploration of female sex work. Tijuana, Mexico. Arch Sex Behav 2004;33:343–51.
      OpenUrlCrossRefPubMedWeb of Science
    75. ↵
      1. Szwarcwald CL
      . Taxas de prevalência de HIV e sífilis e conhecimento, atitudes e práticas de risco relacionadas às infecções sexualmente transmissíveis no grupo das mulheres profissionais do sexo, no Brasil. Study funded by the STD, Aids and Viral Hepatitis Department.
    76. ↵
      1. Hyams KC,
      2. Phillips IA,
      3. Tejada A,
      4. et al
      . Three-year incidence study of retroviral and viral hepatitis transmission in a peruvian prostitute population. J Acquir Immune Defic Syndr 1993;6:1353–7.
      OpenUrlPubMed
    77. ↵
      1. Sánchez J,
      2. Gotuzzo E,
      3. Escamilla J,
      4. et al
      . Sexually transmitted infections in female sex workers: reduced by condom use but not by a limited periodic examination program. Sex Transm Dis 1998;25:82–9.
      OpenUrlPubMedWeb of Science
    78. ↵
      1. Wignall FS,
      2. Hyams KC,
      3. Phillips IA,
      4. et al
      . Sexual transmission of human T-lymphotropic virus type I in Peruvian prostitutes. J Med Virol 1992;38:44–8.
      OpenUrlCrossRefPubMedWeb of Science
    79. ↵
      1. Lowndes CM,
      2. Alary M,
      3. Platt L
      . Injection drug use, commercial sex work, and the HIV/STI epidemic in the Russian Federation. Sex Transm Dis 2003;30:46–8.
      OpenUrlPubMedWeb of Science
    80. ↵
      1. Seidlin M,
      2. Krasinski K,
      3. Bebenroth D,
      4. et al
      . Prevalence of HIV infection in New York call girls. J Acquir Immune Defic Syndr 1988;1:150–4. PubMed PMID: 3216302.
      OpenUrlPubMed
    81. ↵
      1. Potterat JJ,
      2. Woodhouse DE,
      3. Muth JB,
      4. et al
      . Estimating the prevalence and career longevity of prostitute women. J Sex Res 1990;27;233–43.
      OpenUrlCrossRefWeb of Science
    82. ↵
      1. Casabona J,
      2. SÁnchez E,
      3. Salinas R,
      4. et al
      . Seroprevalence and risk factors for HIV transmission among female prostitutes: a community survey. Eur J Epidemiol 1990;6:248–52.
      OpenUrlCrossRefPubMed
    83. ↵
      1. Goldenberg SM,
      2. Gallardo Cruz M,
      3. Strathdee SA,
      4. et al
      . Correlates of unprotected sex with female sex workers among male clients in Tijuana, Mexico. Sex Transm Dis 2010;37:319–24. PubMed PMID: 20081558; PubMed Central PMCID: PMC2861913.
      OpenUrlPubMedWeb of Science
    84. ↵
      1. Patterson TL,
      2. Goldenberg S,
      3. Gallardo M,
      4. et al
      . Correlates of HIV, sexually transmitted infections, and associated high-risk behaviors among male clients of female sex workers in Tijuana, Mexico. AIDS 2009;23:1765–71. PubMed PMID: 19584699; PubMed Central PMCID: PMC2804438.
      OpenUrlCrossRefPubMed
    85. ↵
      1. Couture MC,
      2. Soto JC,
      3. Akom E,
      4. et al
      . Clients of female sex workers in Gonaives and St-Marc, Haiti characteristics, sexually transmitted infection prevalence and risk factors. Sex Transm Dis 2008;35:849–55. PubMed PMID: 18580821.
      OpenUrlCrossRefPubMed
    86. ↵
      1. Jin X,
      2. Smith K,
      3. Chen RY,
      4. et al
      . HIV prevalence and risk behaviors among male clients of female sex workers in Yunnan, China. J Acquir Immune Defic Syndr 2010;53:131–5. PubMed PMID: 19730110; PubMed Central PMCID: PMC2799544.
      OpenUrlCrossRefPubMed
    87. ↵
      1. Subramanian T,
      2. Gupte MD,
      3. Paranjape RS,
      4. et al
      . HIV, sexually transmitted infections and sexual behaviour of male clients of female sex workers in Andhra Pradesh, Tamil Nadu and Maharashtra, India: results of a cross-sectional survey. AIDS 2008;22(Suppl 5):S69–79. PubMed PMID: 19098481.
      OpenUrlCrossRefPubMedWeb of Science
    88. ↵
      1. Xantidis L,
      2. McCabe MP
      . Personality characteristics of male clients of female commercial sex workers in Australia. Arch Sex Behav 2000;29:165–76. PubMed PMID: 10842724.
      OpenUrlCrossRefPubMedWeb of Science
    89. ↵
      1. Lowndes CM,
      2. Alary M,
      3. Gnintoungbé CA,
      4. et al
      . Management of sexually transmitted diseases and HIV prevention in men at high risk: targeting clients and non-paying sexual partners of female sex workers in Benin. AIDS 2000;14:2523–34. PubMed PMID: 11101064.
      OpenUrlCrossRefPubMedWeb of Science
    90. ↵
      1. Voeten HA,
      2. Egesah OB,
      3. Ondiege MY,
      4. et al
      . Clients of female sex workers in Nyanza province, Kenya: a core group in STD/HIV transmission. Sex Transm Dis 2002;29:444–52. PubMed PMID: 12172528.
      OpenUrlPubMedWeb of Science
    91. ↵
      1. McCurdy SA,
      2. Ross MW,
      3. Williams ML,
      4. et al
      . Flashblood: blood sharing among female injecting drug users in Tanzania. Addiction 2010;105:1062–70. Epub 2010 Mar 12.
      OpenUrlCrossRefPubMedWeb of Science
    92. ↵
      1. Mahanta J,
      2. Medhi GK,
      3. Paranjape RS,
      4. et al
      . Injecting and sexual risk behaviours, sexually transmitted infections and HIV prevalence in injecting drug users in three states in India. AIDS 2008;22(Suppl 5):S59–68.
      OpenUrl
    93. ↵
      1. Ross M,
      2. McCurdy S,
      3. Kilonzo G,
      4. et al
      . Drug use careers and blood-borne pathogen risk behavior in male and female Tanzanian heroin injectors. Am J Trop Med Hyg 2008;79:338–43.
      OpenUrlAbstract/FREE Full Text
    94. ↵
      1. Wright NH,
      2. Vanichseni S,
      3. Akarasewi P,
      4. et al
      . Was the 1988 HIV epidemic among Bangkok's injecting drug users a common source outbreak? AIDS 1994;8:529–32.
      OpenUrlCrossRefPubMedWeb of Science
    95. ↵
      1. Buavirat A,
      2. Page-Shafer K,
      3. van Griensven GJ,
      4. et al
      . Risk of prevalent HIV infection associated with incarceration among injecting drug users in Bangkok, Thailand: case-control study. BMJ 2003;326:308.
      OpenUrlAbstract/FREE Full Text
    96. ↵
      1. Go VF,
      2. Frangakis C,
      3. Nam LV,
      4. et al
      . Characteristics of high-risk HIV-positive IDUs in Vietnam: implications for future interventions. Subst Use Misuse 2011;46:381–9.
      OpenUrlCrossRefPubMedWeb of Science
    97. ↵
      1. Kermode M,
      2. Singh LB,
      3. Raju RK,
      4. et al
      . Injections for health-related reasons amongst injecting drug users in New Delhi and Imphal, India. Public Health 2006;120:634–40. Epub 2006 Jun 5.
      OpenUrlCrossRefPubMedWeb of Science
    98. ↵
      1. Lee KC,
      2. Lim WW,
      3. Lee SS
      . High prevalence of HCV in a cohort of injectors on methadone substitution treatment. J Clin Virol 2008;41:297–300. Epub 2008 Jan 10.
      OpenUrlCrossRefPubMed
    99. ↵
      1. Azim T,
      2. Chowdhury EI,
      3. Reza M,
      4. et al
      . Prevalence of infections, HIV risk behaviors and factors associated with HIV infection among male injecting drug users attending a needle/syringe exchange program in Dhaka, Bangladesh. Subst Use Misuse 2008;43:2124–44.
      OpenUrlCrossRefPubMedWeb of Science
    100. ↵
      1. Bautista CT,
      2. Todd CS,
      3. Abed AM,
      4. et al
      . Effects of duration of injection drug use and age at first injection on HCV among IDU in Kabul, Afghanistan. J Public Health (Oxf) 2010;32:336–41. Epub 2010 Apr 26.
      OpenUrlAbstract/FREE Full Text
    101. ↵
      1. Beyrer C,
      2. Patel Z,
      3. Stachowiak JA,
      4. et al
      . Characterization of the emerging HIV type 1 and HCV epidemics among injecting drug users in Dushanbe, Tajikistan. AIDS Res Hum Retroviruses 2009;25:853–60.
      OpenUrlCrossRefPubMedWeb of Science
    102. ↵
      1. Niccolai LM,
      2. Verevochkin SV,
      3. Toussova OV,
      4. et al
      . Estimates of HIV incidence among drug users in St. Petersburg, Russia: continued growth of a rapidly expanding epidemic. Eur J Public Health 2011;21:613–9.
      OpenUrlAbstract/FREE Full Text
    103. ↵
      1. Quan VM,
      2. Go VF,
      3. Nam le V,
      4. et al
      . Risks for HIV, HBV, and HCV infections among male injection drug users in northern Vietnam: a case-control study. AIDS Care 2009;21:7–16.
      OpenUrlCrossRefPubMed
    104. ↵
      1. Todd CS,
      2. Abed AM,
      3. Scott PT,
      4. et al
      . Correlates of receptive and distributive needle sharing among injection drug users in Kabul, Afghanistan. Am J Drug Alcohol Abuse 2008;34:91–100.
      OpenUrlCrossRefPubMedWeb of Science
    105. ↵
      1. Altaf A,
      2. Shah SA,
      3. Zaidi NA,
      4. et al
      . High risk behaviors of injection drug users registered with harm reduction programme in Karachi, Pakistan. Harm Reduct J 2007;4:7.
      OpenUrlCrossRefPubMed
    106. ↵
      1. Azim T,
      2. Chowdhury EI,
      3. Reza M,
      4. et al
      . Vulnerability to HIV infection among sex worker and non-sex worker female injecting drug users in Dhaka, Bangladesh: evidence from the baseline survey of a cohort study. Harm Reduct J 2006;3:33.
      OpenUrlCrossRefPubMed
    107. ↵
      1. Zhao M,
      2. Du J,
      3. Lu GH,
      4. et al
      . HIV sexual risk behaviors among injection drug users in Shanghai. Drug Alcohol Depend 2006;82(Suppl 1):S43–7.
      OpenUrlCrossRefPubMedWeb of Science
    108. ↵
      1. Stoové MA,
      2. Dietze PM,
      3. Aitken CK,
      4. et al
      . Mortality among injecting drug users in Melbourne: a 16-year follow-up of the Victorian Injecting Cohort Study (VICS). Drug Alcohol Depend 2008;96:281–5. Epub 2008 Apr 22.
      OpenUrlCrossRefPubMedWeb of Science
    109. ↵
      1. Maher L,
      2. Li J,
      3. Jalaludin B,
      4. et al
      . High hepatitis C incidence in new injecting drug users: a policy failure? Aust N Z J Public Health 2007;31:30–5.
      OpenUrlCrossRefPubMed
    110. ↵
      1. Darke S,
      2. Kelly E,
      3. Ross J
      . Drug driving among injecting drug users in Sydney, Australia: prevalence, risk factors and risk perceptions. Addiction 2004;99:175–85.
      OpenUrlCrossRefPubMedWeb of Science
    111. ↵
      1. Day C,
      2. Conroy E,
      3. Lowe J,
      4. et al
      . Patterns of drug use and associated harms among rural injecting drug users: comparisons with metropolitan injecting drug users. Aust J Rural Health 2006;14:120–5.
      OpenUrlCrossRefPubMed
    112. ↵
      1. Iversen J,
      2. Wand H,
      3. Gonnermann A,
      4. et al
      . Gender differences in hepatitis C antibody prevalence and risk behaviours amongst people who inject drugs in Australia 1998–2008. Int J Drug Policy 2010;21:471–6.
      OpenUrlCrossRefPubMedWeb of Science
    113. ↵
      1. Lenton S,
      2. Kerry K,
      3. Loxley W,
      4. et al
      . Citizens who inject drugs: the ‘Fitpack’ study. Int J Drug Policy 2000;11:285–97.
      OpenUrlCrossRefPubMed
    114. ↵
      1. White JM,
      2. Dyer KR,
      3. Ali RL,
      4. et al
      . Injecting behaviour and risky needle use amongst methadone maintenance clients. Drug Alcohol Depend 1994;34:113–19.
      OpenUrlCrossRefPubMedWeb of Science
    115. ↵
      1. Miller ER,
      2. Hellard ME,
      3. Bowden S,
      4. et al
      . Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia. J Infect 2009;58:375–82. Epub 2009 Mar 27.
      OpenUrlCrossRefPubMedWeb of Science
    116. ↵
      1. Bryant J,
      2. Treloar C
      . Initiators: an examination of young injecting drug users who initiate others to injecting. AIDS Behav 2008;12:885–90. Epub 2007 Dec 21.
      OpenUrlCrossRefPubMedWeb of Science
    117. ↵
      1. Hellard ME,
      2. Nguyen OK,
      3. Guy RJ,
      4. et al
      . The prevalence and risk behaviours associated with the transmission of blood-borne viruses among ethnic-Vietnamese injecting drug users. Aust N Z J Public Health 2006;30:519–25.
      OpenUrlCrossRefPubMedWeb of Science
    118. ↵
      1. Cao W,
      2. Treloar C
      . Comparison of needle and syringe programme attendees and non-attendees from a high drug-using area in Sydney, New South Wales. Drug Alcohol Rev 2006;25:439–44.
      OpenUrlCrossRefPubMedWeb of Science
    119. ↵
      1. Roxburgh A,
      2. Degenhardt L,
      3. Breen C
      . Drug use and risk behaviours among injecting drug users: a comparison between sex workers and non-sex workers in Sydney, Australia. Harm Reduct J 2005;2:7.
      OpenUrlCrossRefPubMed
    120. ↵
      1. Copeland L,
      2. Budd J,
      3. Robertson JR,
      4. et al
      . Changing patterns in causes of death in a cohort of injecting drug users, 1980–2001. Arch Intern Med 2004;164:1214–20.
      OpenUrlCrossRefPubMedWeb of Science
    121. ↵
      1. Smyth BP,
      2. Keenan E,
      3. O'Connor JJ
      . Evaluation of the impact of Dublin's expanded harm reduction programme on prevalence of hepatitis C among short-term injecting drug users. J Epidemiol Community Health 1999;53:434–5.
      OpenUrlCrossRefPubMedWeb of Science
    122. ↵
      1. Karapetyan AF,
      2. Sokolovsky YV,
      3. Araviyskaya ER,
      4. et al
      . Syphilis among intravenous drug-using population: epidemiological situation in St. Petersburg, Russia. Int J STD AIDS 2002;13:618–23.
      OpenUrlAbstract/FREE Full Text
    123. ↵
      1. Stormer A,
      2. Tun W,
      3. Guli L,
      4. et al
      . An analysis of respondent driven sampling with Injection Drug Users (IDU) in Albania and the Russian Federation. J Urban Health 2006;83(6 Suppl):i73–82.
      OpenUrlPubMedWeb of Science
    124. ↵
      1. De los Cobos Calleja T,
      2. Casanueva Gutiérrez M,
      3. Jove González C
      . Perfil de los usuarios de drogas ingresados en un hospital. An Med Interna (Madrid) 2003;20:504–9.
      OpenUrl
    125. ↵
      1. Cassin S,
      2. Geoghegan T,
      3. Cox G
      . Young injectors: a comparative analysis of risk behaviour. Ir J Med Sci 1998;167:234–7.
      OpenUrlPubMedWeb of Science
    126. ↵
      1. Dolan KA,
      2. Donoghoe MC,
      3. Stimson GV
      . Reductions in HIV risk behaviour and stable HIV prevalence in syringe-exchange clients and other injectors in England. Drug Alcohol Rev 1993;12:133–42.
      OpenUrlCrossRefPubMed
    127. ↵
      1. Lidman C,
      2. Norden L,
      3. Kåberg M,
      4. et al
      . Hepatitis C infection among injection drug users in Stockholm Sweden: prevalence and gender. Scand J Infect Dis 2009;41:679–84.
      OpenUrlCrossRefPubMed
    128. ↵
      1. Muga R,
      2. Roca J,
      3. Egea JM,
      4. et al
      . Mortality of HIV-positive and HIV-negative heroin abusers as a function of duration of injecting drug use. J Acquir Immune Defic Syndr 2000;23:332–8.
      OpenUrlPubMedWeb of Science
    129. ↵
      1. Rhodes T,
      2. Donoghoe M,
      3. Hunter G,
      4. et al
      . Sexual behaviour of drug injectors in London: implications for HIV transmission and HIV prevention. Addiction 1994;89:1085–96.
      OpenUrlCrossRefPubMedWeb of Science
    130. ↵
      1. Steffen T,
      2. Blättler R,
      3. Gutzwiller F,
      4. et al
      . HIV and hepatitis virus infections among injecting drug users in a medically controlled heroin prescription programme. Eur J Public Health 2001;11:425–30.
      OpenUrlAbstract/FREE Full Text
    131. ↵
      1. Gyarmathy VA,
      2. Neaigus A,
      3. Li N,
      4. et al
      . Infection disclosure in the injecting dyads of Hungarian and Lithuanian injecting drug users who self-reported being infected with hepatitis C virus or human immunodeficiency virus. Scand J Infect Dis 2011;43:32–42.
      OpenUrlCrossRefPubMed
    132. ↵
      1. Kolarić B,
      2. Stajduhar D,
      3. Gajnik D,
      4. et al
      . Seroprevalence of blood-borne infections and population sizes estimates in a population of injecting drug users in Croatia. Cent Eur J Public Health 2010;18:104–9.
      OpenUrlPubMed
    133. ↵
      1. Vlahov D,
      2. Safaien M,
      3. Lai S,
      4. et al
      . Sexual and drug risk-related behaviours after initiating highly active antiretroviral therapy among injection drug users. AIDS 2001;15:2311–16.
      OpenUrlCrossRefPubMedWeb of Science
    134. ↵
      1. Hickman M,
      2. Hope V,
      3. Brady T,
      4. et al
      . Hepatitis C virus (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004. J Viral Hepat 2007;14:645–52.
      OpenUrlCrossRefPubMedWeb of Science
    135. ↵
      1. Folch C,
      2. Meroño M,
      3. Casabona J
      . Factors associated with sharing syringes among street-recruited injecting drug users. Med Clin (Barc) 2006;127:526–32.
      OpenUrlCrossRefPubMed
    136. ↵
      1. Booth RE,
      2. Kwiatkowski CF,
      3. Brewster JT,
      4. et al
      . Predictors of HIV sero-status among drug injectors at three Ukraine sites. AIDS 2006;20:2217–23.
      OpenUrlCrossRefPubMedWeb of Science
    137. ↵
      1. Muga R,
      2. Sanvisens A,
      3. Bolao F,
      4. et al
      . Significant reductions of HIV prevalence but not of hepatitis C virus infections in injection drug users from metropolitan Barcelona: 1987–2001. Drug Alcohol Depend 2006;82(Suppl 1):S29–33.
      OpenUrlCrossRefPubMedWeb of Science
    138. ↵
      1. Backmund M,
      2. Meyer K,
      3. Schuetz C,
      4. et al
      . Factors associated with exposure to hepatitis B virus in injection drug users. Drug Alcohol Depend 2006;84:154–9. Epub 2006 Feb 14.
      OpenUrlCrossRefPubMedWeb of Science
    139. ↵
      1. Platt L,
      2. Rhodes T,
      3. Lowndes CM,
      4. et al
      . Impact of gender and sex work on sexual and injecting risk behaviors and their association with HIV positivity among injecting drug users in an HIV epidemic in Togliatti City, Russian Federation. Sex Transm Dis 2005;32:605–12.
      OpenUrlCrossRefPubMedWeb of Science
    140. ↵
      1. Gyarmathy VA,
      2. Neaigus A
      . Marginalized and socially integrated groups of IDUs in Hungary: potential bridges of HIV infection. J Urban Health 2005;82(3 Suppl 4):iv101–12.
      OpenUrlCrossRefPubMedWeb of Science
    141. ↵
      1. Maliphant J,
      2. Scott J
      . Use of the femoral vein (‘groin injecting’) by a sample of needle exchange clients in Bristol, UK. Harm Reduct J 2005;2:6.
      OpenUrlCrossRefPubMed
    142. ↵
      1. Kivelä P,
      2. Krol A,
      3. Simola S,
      4. et al
      . HIV outbreak among injecting drug users in the Helsinki region: social and geographical pockets. Eur J Public Health 2007;17:381–6. Epub 2006 Nov 27.
      OpenUrlAbstract/FREE Full Text
    143. ↵
      1. de Azevedo RC,
      2. Botega NJ,
      3. Guimarães LA
      . Crack users, sexual behavior and risk of HIV infection. Rev Bras Psiquiatr 2007;29:26–30.
      OpenUrlCrossRefPubMed
    144. ↵
      1. Marchesini AM,
      2. Prá-Baldi ZP,
      3. Mesquita F,
      4. et al
      . Hepatitis B and C among injecting drug users living with HIV in São Paulo, Brazil). Rev Saude Publica 2007;41(Suppl 2):57–63.
      OpenUrlCrossRefPubMed
    145. ↵
      1. Dourado I,
      2. Andrade T,
      3. Carpenter C,
      4. et al
      . Risk factors for human T cell lymphotropic virus Type I among injecting drug users in northeast Brazil: possibly greater efficiency of male to female transmission. Mem Inst Oswaldo Cruz, Rio de Janeiro 1999;94:13–8.
      OpenUrlPubMedWeb of Science
    146. ↵
      1. Lima ES,
      2. Friedman SR,
      3. Bastos FI,
      4. et al
      . Risk factors for HIV-1 seroprevalence among drug injectors in the cocaine-using environment of Rio de Janeiro. Addiction 1994;89:689–98.
      OpenUrlCrossRefPubMedWeb of Science
    147. ↵
      1. Oliveira Mde L,
      2. Bastos FI,
      3. Telles PR,
      4. et al
      . Epidemiological and genetic analyses of Hepatitis C virus transmission among young/short- and long-term injecting drug users from Rio de Janeiro, Brazil. J Clin Virol 2009;44:200–6. Epub 2009 Feb 4.
      OpenUrlCrossRefPubMed
    148. ↵
      1. Caiaffa WT,
      2. Bastos FI,
      3. Freitas LL,
      4. et al
      . Projeto AjUDE-Brasil I; Projeto AjUDE-Brasil II.The contribution of two Brazilian multi-center studies to the assessment of HIV and HCV infection and prevention strategies among injecting drug users: the AjUDE-Brasil I and II Projects. Cad Saude Publica 2006;22:771–82. Epub 2006 Apr 5.
      OpenUrlCrossRefPubMed
    149. ↵
      1. Huo D,
      2. Bailey SL,
      3. Ouellet LJ
      . Cessation of injection drug use and change in injection frequency: the Chicago needle exchange evaluation study. Addiction 2006;101:1606–13.
      OpenUrlCrossRefPubMedWeb of Science
    150. ↵
      1. Hahn JA,
      2. Page-Shafer K,
      3. Lum PJ,
      4. et al
      . Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology 2001;34:180–7.
      OpenUrlCrossRefPubMedWeb of Science
    151. ↵
      1. Miller CL,
      2. Johnston C,
      3. Spittal PM,
      4. et al
      . Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology 2002;36:737–42.
      OpenUrlCrossRefPubMedWeb of Science
    152. ↵
      1. Neaigus A,
      2. Friedman SR,
      3. Jose B,
      4. et al
      . High-risk personal networks and syringe sharing as risk factors for HIV infection among new drug injectors. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:499–509.
      OpenUrlPubMedWeb of Science
    153. ↵
      1. Roy E,
      2. Boudreau JF,
      3. Boivin JF
      . Hepatitis C virus incidence among young street-involved IDUs in relation to injection experience. Drug Alcohol Depend 2009;102:158–61. Epub 2009 Feb 28.
      OpenUrlCrossRefPubMedWeb of Science
    154. ↵
      1. Chitwood DD,
      2. Comerford M,
      3. Kitner KR,
      4. et al
      . A comparison of HIV risk behaviors between new and long-term injection drug users. Subst Use Misuse 2001;36:91–111.
      OpenUrlCrossRefPubMedWeb of Science
    155. ↵
      1. Corsi KF,
      2. Lehman WK,
      3. Booth RE
      . The effect of methadone maintenance on positive outcomes for opiate injection drug users. J Subst Abuse Treat 2009;37:120–6. Epub 2009 Jan 15.
      OpenUrlCrossRefPubMedWeb of Science
    156. ↵
      1. Debeck K,
      2. Kerr T,
      3. Bird L,
      4. et al
      . Injection drug use cessation and use of North America's first medically supervised safer injecting facility. Drug Alcohol Depend 2011;113:172–6.
      OpenUrlCrossRefPubMedWeb of Science
    157. ↵
      1. Doherty MC,
      2. Garfein RS,
      3. Monterroso E,
      4. et al
      . Correlates of HIV infection among young adult short-term injection drug users. AIDS 2000;14:717–26.
      OpenUrlCrossRefPubMedWeb of Science
    158. ↵
      1. Garfein RS,
      2. Doherty MC,
      3. Monterroso ER,
      4. et al
      . Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S11–19.
      OpenUrlCrossRefPubMed
    159. ↵
      1. Mehta SH,
      2. Galai N,
      3. Astemborski J,
      4. et al
      . HIV incidence among injection drug users in Baltimore, Maryland (1988–2004). J Acquir Immune Defic Syndr 2006;43:368–72.
      OpenUrlCrossRefPubMedWeb of Science
    160. ↵
      1. Pouget ER,
      2. Deren S,
      3. Fuller CM,
      4. et al
      . Receptive syringe sharing among injection drug users in Harlem and the Bronx during the New York State Expanded Syringe Access Demonstration Program. J Acquir Immune Defic Syndr 2005;39:471–7.
      OpenUrlCrossRefPubMedWeb of Science
    161. ↵
      1. Schütz CG,
      2. Rapiti E,
      3. Vlahov D,
      4. et al
      . Suspected determinants of enrollment into detoxification and methadone maintenance treatment among injecting drug users.
    162. ↵
      1. Steensma C,
      2. Boivin JF,
      3. Blais L,
      4. et al
      . Cessation of injecting drug use among street-based youth. J Urban Health 2005;82:622–37. Epub 2005 Sep 29.
      OpenUrlPubMed
    163. ↵
      1. Wood E,
      2. Stoltz JA,
      3. Zhang R,
      4. et al
      . Circumstances of first crystal methamphetamine use and initiation of injection drug use among high-risk youth. Drug Alcohol Rev 2008;27:270–6.
      OpenUrlCrossRefPubMedWeb of Science
    164. ↵
      1. Evans JL,
      2. Hahn JA,
      3. Lum PJ,
      4. et al
      . Predictors of injection drug use cessation and relapse in a prospective cohort of young injection drug users in San Francisco, CA (UFO Study). Drug Alcohol Depend 2009;101:152–7. Epub 2009 Jan 31. Drug Alcohol Depend 2009;101:152–7. Epub 2009 Jan 31.
      OpenUrlCrossRefPubMedWeb of Science
    165. ↵
      1. Lum PJ,
      2. Hahn JA,
      3. Shafer KP,
      4. et al
      . Hepatitis B virus infection and immunization status in a new generation of injection drug users in San Francisco. J Viral Hepat 2008;15:229–36.
      OpenUrlPubMed
    166. ↵
      1. Shaw SY,
      2. Shah L,
      3. Jolly AM,
      4. et al
      . Determinants of injection drug user (IDU) syringe sharing: the relationship between availability of syringes and risk network member characteristics in Winnipeg, Canada. Addiction 2007;102:1626–35.
      OpenUrlCrossRefPubMedWeb of Science
    167. ↵
      1. Neaigus A,
      2. Gyarmathy VA,
      3. Miller M,
      4. et al
      . Injecting and sexual risk correlates of HBV and HCV seroprevalence among new drug injectors. Drug Alcohol Depend 2007;89:234–43. Epub 2007 Feb 7.
      OpenUrlCrossRefPubMedWeb of Science
    168. ↵
      1. Hagan H,
      2. Campbell J,
      3. Thiede H,
      4. et al
      . Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Rep 2006;121:710–19.
      OpenUrlPubMedWeb of Science
    169. ↵
      1. Miller CL,
      2. Kerr T,
      3. Strathdee SA,
      4. et al
      . Factors associated with premature mortality among young injection drug users in Vancouver. Harm Reduct J 2007;4:1.
      OpenUrlCrossRefPubMed
    170. ↵
      1. Wylie JL,
      2. Shah L,
      3. Jolly AM
      . Demographic, risk behaviour and personal network variables associated with prevalent hepatitis C, hepatitis B, and HIV infection in injection drug users in Winnipeg, Canada. BMC Public Health 2006;6:229.
      OpenUrlCrossRefPubMed
    171. ↵
      1. Miller CL,
      2. Strathdee SA,
      3. Spittal PM,
      4. et al
      . Elevated rates of HIV infection among young Aboriginal injection drug users in a Canadian setting. Harm Reduct J 2006;3:9.
      OpenUrlCrossRefPubMed
    172. ↵
      1. Lum PJ,
      2. Sears C,
      3. Guydish J
      . Injection risk behavior among women syringe exchangers in San Francisco. Subst Use Misuse 2005;40:1681–96.
      OpenUrlCrossRefPubMedWeb of Science
    173. ↵
      1. Pugatch D,
      2. Anderson BJ,
      3. O'Connell JV,
      4. et al
      . HIV and HCV testing for young drug users in Rhode Island. J Adolesc Health 2006;38:302–4.
      OpenUrlCrossRefPubMedWeb of Science
    174. ↵
      1. Hart TA,
      2. James CA,
      3. Hagan CM,
      4. et al
      . HIV optimism and high-risk sexual behavior in two cohorts of men who have sex with men. J Assoc Nurses AIDS Care 2010;21:439–43. Epub 2010 Jul 24. PubMed PMID: 20656521.
      OpenUrlCrossRefPubMedWeb of Science
    175. ↵
      1. Golub SA,
      2. Kowalczyk W,
      3. Weinberger CL,
      4. et al
      . Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr 2010;54:548–55. PubMed PMID: 20512046; PubMed Central PMCID: PMC2908204.
      OpenUrlCrossRefPubMedWeb of Science
    176. ↵
      1. Carey JW,
      2. Mejia R,
      3. Bingham T,
      4. et al
      . Drug use, high-risk sex behaviors, and increased risk for recent HIV infection among men who have sex with men in Chicago and Los Angeles. AIDS Behav 2009;13:1084–96. Epub 2008 May 23. PubMed PMID: 18498049.
      OpenUrlCrossRefPubMedWeb of Science
    177. ↵
      1. Dodds JP,
      2. Johnson AM,
      3. Parry JV,
      4. et al
      . A tale of three cities: persisting high HIV prevalence, risk behaviour and undiagnosed infection in community samples of men who have sex with men. Sex Transm Infect 2007;83:392–6. Epub 2007 May 1. Erratum in: Sex Transm Infect 2007;83:500. PubMed PMID: 17472978; PubMed Central PMCID: PMC2659037.
      OpenUrlAbstract/FREE Full Text
    178. ↵
      1. Danta M,
      2. Brown D,
      3. Bhagani S,
      4. et al
      . HIV and Acute HCV (HAAC) group. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007;21:983–91. PubMed PMID: 17457092.
      OpenUrlCrossRefPubMedWeb of Science
    179. ↵
      1. Koblin BA,
      2. Chesney MA,
      3. Husnik MJ,
      4. et al
      . EXPLORE Study Team. High-risk behaviors among men who have sex with men in 6 US cities: baseline data from the EXPLORE Study. Am J Public Health 2003;93:926–32. Erratum in: Am J Public Health 2003;93:1203. PubMed PMID: 12773357; PubMed Central PMCID: PMC1447872.
      OpenUrlCrossRefPubMedWeb of Science
    180. ↵
      1. Thomas SM,
      2. Tse DB,
      3. Ketner DS,
      4. et al
      . CCR5 expression and duration of high risk sexual activity among HIV-seronegative men who have sex with men. AIDS 2006;20:1879–83. PubMed PMID: 16954729; PubMed Central PMCID: PMC1630600.
      OpenUrlCrossRefPubMedWeb of Science
    181. ↵
      1. Mansergh G,
      2. Flores S,
      3. Koblin B,
      4. et al
      . Project MIX Study Group. Alcohol and drug use in the context of anal sex and other factors associated with sexually transmitted infections: results from a multi-city study of high-risk men who have sex with men in the USA. Sex Transm Infect 2008;84:509–11. PubMed PMID: 19028957.
      OpenUrlAbstract/FREE Full Text

    Supplementary materials

    • Supplementary Data

      This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

      Files in this Data Supplement:

    Footnotes

    • Contributions EF: Conception and design of the study, acquisition of data, analysis and interpretation of data, article draft, paper review for important intellectual content, final approval of the version to be published. PC and MM: Conception and design of the study, analysis and interpretation of data, paper review for important intellectual content, final approval of the version to be published. TB: Interpretation of data, paper review for important intellectual content, final approval of the version to be published.

    • Competing interests None.

    • Provenance and peer review Commissioned; externally peer reviewed.

    • Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/